Matthias M Heck1, Robert Tauber2, Sebastian Schwaiger3, Margitta Retz2, Calogero D'Alessandria4, Tobias Maurer2, Andrei Gafita4, Hans-Jürgen Wester5, Jürgen E Gschwend2, Wolfgang A Weber4, Markus Schwaiger4, Karina Knorr4, Matthias Eiber4. 1. Department of Urology, Medical Center rechts der Isar, Technical University of Munich, Munich, Germany. Electronic address: matthias.heck@tum.de. 2. Department of Urology, Medical Center rechts der Isar, Technical University of Munich, Munich, Germany. 3. Department of Urology, Medical Center rechts der Isar, Technical University of Munich, Munich, Germany; Department of Nuclear Medicine, Medical Center rechts der Isar, Technical University of Munich, Munich, Germany. 4. Department of Nuclear Medicine, Medical Center rechts der Isar, Technical University of Munich, Munich, Germany. 5. Pharmaceutical Radiochemistry, Technical University of Munich, Garching, Germany.
Abstract
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is increasingly being used in metastatic castration-resistant prostate cancer (mCRPC). The objective of this study is to report our clinical experience with RLT using 177-lutetium-labeled PSMA-I&T. A total of 100 patients were treated under a compassionate use protocol with a total number of 319 cycles (median two cycles, range 1-6). Eligibility criteria included previous treatment with abiraterone or enzalutamide, previous taxane-based chemotherapy or chemoineligibility, and positive PSMA-ligand uptake at positron-emission tomography scan. The 177Lu-PSMA-I&T was given 6-8 weekly with an activity of 7.4 GBq up to six cycles. The median number of previous mCRPC regimens was 3 (range 1-6), and 35 patients had visceral metastases. Prostate-specific antigen decline of ≥50% was achieved in 38 patients, median clinical progression-free survival (cPFS) was 4.1mo, and median overall survival (OS) was 12.9mo. Subgroup analyses identified an association of visceral metastases with a poor prostate-specific antigen (PSA) response and shorter cPFS and OS, and an association of rising lactate dehydrogenase (LDH) with shorter cPFS and OS. Patients achieving PSA decline of ≥50% within 12wk of treatment showed longer cPFS and OS. Treatment-emergent hematologic grade 3/4 toxicities were anemia (9%), thrombocytopenia (4%), and neutropenia (6%). Grade 3/4 nonhematologic toxicities were not observed. RLT with 177Lu-PSMA-I&T showed good activity in more than one-third of patients with late-stage mCRPC at low toxicity. Presence of visceral metastases and rising LDH were associated with worse treatment outcome. PATIENT SUMMARY: We analyzed the treatment outcome and toxicity of prostate-specific membrane antigen-targeted radioligand therapy in patients with metastatic castration-resistant prostate cancer. We found that a good treatment response could be achieved in a subgroup of patients with few side effects. We also observed that treatment outcome was worse in patients with organ metastases and elevated lactate dehydrogenase in blood tests.
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is increasingly being used in metastatic castration-resistant prostate cancer (mCRPC). The objective of this study is to report our clinical experience with RLT using 177-lutetium-labeled PSMA-I&T. A total of 100 patients were treated under a compassionate use protocol with a total number of 319 cycles (median two cycles, range 1-6). Eligibility criteria included previous treatment with abiraterone or enzalutamide, previous taxane-based chemotherapy or chemoineligibility, and positive PSMA-ligand uptake at positron-emission tomography scan. The 177Lu-PSMA-I&T was given 6-8 weekly with an activity of 7.4 GBq up to six cycles. The median number of previous mCRPC regimens was 3 (range 1-6), and 35 patients had visceral metastases. Prostate-specific antigen decline of ≥50% was achieved in 38 patients, median clinical progression-free survival (cPFS) was 4.1mo, and median overall survival (OS) was 12.9mo. Subgroup analyses identified an association of visceral metastases with a poor prostate-specific antigen (PSA) response and shorter cPFS and OS, and an association of rising lactate dehydrogenase (LDH) with shorter cPFS and OS. Patients achieving PSA decline of ≥50% within 12wk of treatment showed longer cPFS and OS. Treatment-emergent hematologic grade 3/4 toxicities were anemia (9%), thrombocytopenia (4%), and neutropenia (6%). Grade 3/4 nonhematologic toxicities were not observed. RLT with 177Lu-PSMA-I&T showed good activity in more than one-third of patients with late-stage mCRPC at low toxicity. Presence of visceral metastases and rising LDH were associated with worse treatment outcome. PATIENT SUMMARY: We analyzed the treatment outcome and toxicity of prostate-specific membrane antigen-targeted radioligand therapy in patients with metastatic castration-resistant prostate cancer. We found that a good treatment response could be achieved in a subgroup of patients with few side effects. We also observed that treatment outcome was worse in patients with organ metastases and elevated lactate dehydrogenase in blood tests.
Authors: Hian Liang Huang; Aaron Kian Ti Tong; Sue Ping Thang; Sean Xuexian Yan; Winnie Wing Chuen Lam; Kelvin Siu Hoong Loke; Charlene Yu Lin Tang; Lenith Tai Jit Cheng; Gideon Su Kai Ooi; Han Chung Low; Butch Maulion Magsombol; Wei Ying Tham; Charles Xian Yang Goh; Colin Jingxian Tan; Yiu Ming Khor; Sumbul Zaheer; Pushan Bharadwaj; Wanying Xie; David Chee Eng Ng Journal: Nucl Med Mol Imaging Date: 2019-01-25
Authors: Albertus W Hensbergen; Tessa Buckle; Danny M van Willigen; Margret Schottelius; Mick M Welling; Felicia A van der Wijk; Tobias Maurer; Henk G van der Poel; Gabri van der Pluijm; Wytske M van Weerden; Hans-Jürgen Wester; Fijs W B van Leeuwen Journal: J Nucl Med Date: 2019-09-03 Impact factor: 10.057
Authors: Mohammad S Sadaghiani; Sara Sheikhbahaei; Rudolf A Werner; Kenneth J Pienta; Martin G Pomper; Lilja B Solnes; Michael A Gorin; Nae-Yuh Wang; Steven P Rowe Journal: Eur Urol Date: 2021-04-08 Impact factor: 20.096
Authors: Jeremie Calais; Andrei Gafita; Matthias Eiber; Wesley R Armstrong; Jeannine Gartmann; Pan Thin; Kathleen Nguyen; Vincent Lok; Laura Gosa; Tristan Grogan; Rouzbeh Esfandiari; Martin Allen-Auerbach; Andrew Quon; Shadfar Bahri; Pawan Gupta; Linda Gardner; David Ranganathan; Roger Slavik; Magnus Dahlbom; Ken Herrmann; Ebrahim Delpassand; Wolfgang P Fendler; Johannes Czernin Journal: J Nucl Med Date: 2021-05-20 Impact factor: 10.057
Authors: Bastiaan M Privé; Peter H J Slootbeek; Babette I Laarhuis; Samhita Pamidimarri Naga; Maarten J van der Doelen; Ludwike W M van Kalmthout; Bart de Keizer; Samer Ezziddin; Clemens Kratochwil; Alfred Morgenstern; Frank Bruchertseifer; Marjolijn J L Ligtenberg; J Alfred Witjes; Inge M van Oort; Martin Gotthardt; Sandra Heskamp; Marcel J R Janssen; Winald R Gerritsen; James Nagarajah; Niven Mehra Journal: Prostate Cancer Prostatic Dis Date: 2021-07-12 Impact factor: 5.554